Efficacy and safety comparison of brodalumab versus guselkumab in adultsubjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab. - COBRA

EO Pharma A/S0 个研究点目标入组 120 人开始时间: 2020年10月15日最近更新: 2023年1月9日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 120

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Subject is i:!:18 years of age at the time of screening.
•- Subject has a diagnosis of plaque psoriasis for at least 6 months before
•the first administration of investigational medicinal product (IMP) as
•determined by the investigator.
•- Subject has inadequately controlled plaque psoriasis currently treated
•with ustekinumab, and fulfil ALL of the following criteria:
•- Ustekinumab administered at least 3 times at or higher than the
•approved dose or frequency before randomisation.
•- IGA i:!:2 at screening and baseline.
•- Absolute PASI >3 at screening and baseline.
•- Subject has no evidence of active tuberculosis according to local standard of care for patients requiring initiation of a biologic treatment. Subjects with adequately treated latent tuberculosis, according to local guidelines, are eligible.
•a.DA tuberculosis test can be performed at the central laboratory.
•b.?If a local laboratory test is performed to confirm this criterium, the local laboratory should be assessed before the local testing is performed.
•- Subject who is a woman of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
•* A woman is defined as being of childbearing potential if she is not postmenopausal (at least 12 months with no menses without an alternative medical cause prior to screening) and not surgically sterile
•(hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
•- Subject who is a woman of childbearing potential* must use a highly effective** form of birth control throughout the trial and at least for 12 weeks after last administration of IMP.
•** A highly effective method of birth control is defined as one which results in a low failure rate (less than 10/o per year) such as bilateral tubal occlusion, intrauterine device, intrauterine hormone-releasing system, combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), sexual abstinence (when this is in line with the preferred and usual life style of the subject), or vasectomised partner (given that the subject is monogamous).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 180
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

排除标准

•- Subject was diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions (e.g. eczema) that would interfere with evaluations of the effect of IMP on plaque psoriasis.
•- Subject has clinically important active infections or infestations, chronic, recurrent, or latent infections or infestations, or is immunocompromised (e.g. human immunodeficiency virus).
•- Subject has any systemic disease (e.g. renal failure, heart failure, hypertension, liver disease, diabetes, anaemia) considered by the investigator to be clinically significant and uncontrolled.
•- Subject has a known history of Crohn’s disease.
•- Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
•- Subject has a history of malignancy within 5 years, except for treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
•- Subject has a known history of active tuberculosis.
•- Subject has a history of suicidal behaviour (i.e. ‘actual suicide attempt’, ‘interrupted attempt’, ‘aborted attempt’, or ‘preparatory acts or behaviour’) based on the Columbia-Suicide Severity Rating Scale (CSSRS) questionnaire at screening or baseline.
•- Subject has any suicidal ideation of severity 4 or 5 (‘some intent to act, no plan’ or ‘specific plan and intent’) based on the C-SSRS questionnaire at screening or baseline.
•- Subject has a Patient Health Questionnaire-8 (PHQ-8) score of =10, corresponding to moderate-to-severe depression at screening or baseline.
•- -Subject has previously received more than 1 tumour necrosis factor-a (TNF-a) inhibitor. NOTE: This exclusion criterion is not applicable in this version of the protocol. It is kept to avoid re-numbering of the exclusion criteria.
•-Subject has previously received more than 1 tumour necrosis factor-a (TNF-a) inhibitor. NOTE: This exclusion criterion is not applicable in this version of the protocol. It is kept to avoid re-numbering of the exclusion criteria.
•- Subject has previously been treated with any anti-interleukin (IL)-17A, anti-IL-17 receptor subunit A, or anti-IL-23 besides ustekinumab.
•- Subject has known or suspected hypersensitivity to any component(s) of the IMPs.

研究者

发起方

EO Pharma A/S

相似试验

进行中（未招募）

1 期

Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab.adult subjects with moderate-to-severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858

EUCTR2019-004099-20-GBEO Pharma A/S260

进行中（未招募）

1 期

EUCTR2019-004099-20-NLEO Pharma A/S260

进行中（未招募）

1 期

Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab.

EUCTR2019-004099-20-ATEO Pharma A/S240

进行中（未招募）

1 期

EUCTR2019-004099-20-CZEO Pharma A/S260

进行中（未招募）

1 期

EUCTR2019-004099-20-DEEO Pharma A/S240